Omeros (OMER) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Omeros (NASDAQ:OMER) from a buy rating to a strong-buy rating in a research report report published on Wednesday.

Several other brokerages have also recently commented on OMER. HC Wainwright set a $34.00 target price on shares of Omeros and gave the stock a buy rating in a report on Wednesday, August 29th. ValuEngine upgraded shares of Omeros from a hold rating to a buy rating in a report on Friday, July 6th. Maxim Group increased their target price on shares of Omeros from $25.00 to $32.00 and gave the stock a buy rating in a report on Friday, August 10th. MED restated a reduce rating on shares of Omeros in a report on Monday, July 23rd. Finally, Zacks Investment Research cut shares of Omeros from a hold rating to a sell rating in a report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $27.56.

OMER traded up $0.04 during trading hours on Wednesday, hitting $15.49. 5,550 shares of the company’s stock were exchanged, compared to its average volume of 1,032,484. Omeros has a 1-year low of $8.36 and a 1-year high of $27.00. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -19.32 and a beta of 3.49. The company has a current ratio of 3.95, a quick ratio of 3.94 and a debt-to-equity ratio of -2.31.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.84 million. During the same period last year, the firm earned ($0.33) EPS. The company’s revenue was down 90.1% compared to the same quarter last year. As a group, research analysts predict that Omeros will post -2.48 earnings per share for the current fiscal year.

In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of the stock in a transaction on Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the sale, the vice president now owns 227,645 shares in the company, valued at $5,861,858.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 40,723 shares of the stock in a transaction on Friday, July 27th. The shares were sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the sale, the vice president now owns 219,645 shares of the company’s stock, valued at approximately $4,735,546.20. The disclosure for this sale can be found here. Company insiders own 12.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. increased its holdings in shares of Omeros by 3.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 222,678 shares of the biopharmaceutical company’s stock valued at $2,488,000 after purchasing an additional 6,800 shares during the last quarter. BlackRock Inc. increased its stake in Omeros by 0.9% during the first quarter. BlackRock Inc. now owns 3,965,410 shares of the biopharmaceutical company’s stock worth $44,294,000 after acquiring an additional 34,832 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Omeros by 30.8% during the first quarter. Russell Investments Group Ltd. now owns 29,884 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 7,037 shares during the last quarter. Principal Financial Group Inc. increased its stake in Omeros by 10.2% during the first quarter. Principal Financial Group Inc. now owns 29,433 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 2,723 shares during the last quarter. Finally, Baird Financial Group Inc. increased its stake in Omeros by 69.3% during the first quarter. Baird Financial Group Inc. now owns 105,450 shares of the biopharmaceutical company’s stock worth $1,178,000 after acquiring an additional 43,154 shares during the last quarter. 48.11% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Fundamental Analysis

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply